Baxter International (NYSE:BAX) will issue its quarterly earnings data before the market opens on Thursday, April 26th. Analysts expect the company to announce earnings of $0.64 per share for the quarter. Baxter International has set its Q1 guidance at $0.60-0.62 EPS and its FY18 guidance at $2.72-2.80 EPS.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.77 billion. During the same period last year, the company posted $0.57 earnings per share. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of NYSE:BAX opened at $66.15 on Wednesday. Baxter International has a twelve month low of $53.04 and a twelve month high of $72.58. The firm has a market capitalization of $36,216.31, a PE ratio of 26.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.57 and a quick ratio of 2.05.
Baxter International announced that its Board of Directors has authorized a share buyback plan on Tuesday, February 20th that allows the company to repurchase $1.50 billion in shares. This repurchase authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which was paid on Monday, April 2nd. Stockholders of record on Friday, March 2nd were paid a $0.16 dividend. The ex-dividend date was Thursday, March 1st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.97%. Baxter International’s dividend payout ratio (DPR) is presently 25.81%.
In other news, Director Carole J. Shapazian sold 4,990 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $66.05, for a total transaction of $329,589.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James R. Gavin III sold 18,750 shares of the business’s stock in a transaction dated Wednesday, March 28th. The stock was sold at an average price of $64.56, for a total value of $1,210,500.00. Following the transaction, the director now owns 36,398 shares of the company’s stock, valued at $2,349,854.88. The disclosure for this sale can be found here. Insiders have sold a total of 27,500 shares of company stock valued at $1,783,512 over the last 90 days. Corporate insiders own 0.07% of the company’s stock.
A number of analysts recently commented on BAX shares. Raymond James upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a research report on Wednesday, January 3rd. Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase upgraded Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Evercore ISI started coverage on Baxter International in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 price objective for the company. Finally, Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $71.13.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/25/baxter-international-bax-set-to-announce-earnings-on-thursday.html.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.